Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

Also called NCT03651557

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03651557
Other papers using this trial's data
  • Nelonemdaz Treatment for Patients With Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial Critical care medicine, 2025-04-01 DOI, PubMed 39899673

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03651557. Randomized; triple masking; primary purpose treatment. Start 2018-11-29 (actual); primary completion 2021-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients
Acronym
AWAKE
Intervention (Drug)
Neu2000KWL High-dose group
Intervention (Drug)
Neu2000KWL Low-dose group
Intervention (Drug)
Placebo
Lead sponsor
GNT Pharma (class: industry)
Collaborator
Samsung Medical Center (class: other)
Collaborator
Chonnam National University Hospital (class: other)
Collaborator
Gangnam Severance Hospital (class: other)
Collaborator
Kyungpook National University Hospital (class: other)
Collaborator
Pusan National University Hospital (class: other)
Collaborator
Soonchunhyang University Hospital (class: other)

Record details

Record id
cardio:ct-nct03651557
Content hash
0011a7c6467a69a0cb99bfd968dba8fd9aa57324432ca6226724105a77dd7885